Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice (pages 327–335)
KEISHI HIGASHI, TAKASHI ODA, TAKETOSHI KUSHIYAMA, TOSHITAKE HYODO, MUNEHARU YAMADA, SHIGENOBU SUZUKI, YUTAKA SAKURAI, SOICHIRO MIURA and HIROO KUMAGAI
Version of Record online: 18 NOV 2009 | DOI: 10.1111/j.1440-1797.2009.01253.x
This paper shows that the combination of peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists and candesartan in a non-diabetic model of experimental renal fibrosis is associated with an additive effect. Although lacking in mechanism, this paper has important implications for the potential use of PPAR-γ agonists as antifibrotic therapies in non-diabetic renal disease.